More specifically, they target the B-cell maturation antigen [BCMA (teclistamab, elranatamab)], the orphan G-protein-coupled receptor, class C group 5 member [GPRC5D (talquetamab)] and Fc receptor homologous 5 [FcRH5 antigen (cevostamab)] expressed on MM cells and CD3 receptor expressed on T-cells. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.